Neuvotion sets fall US commercial launch for its FDA-cleared NeuStim stimulator

By Inside BCI · July 27, 2026

Ten years ago, at Battelle Memorial Institute in Columbus, Ohio, an engineer named Chad Bouton led the team that put a Utah microelectrode array into the motor cortex of a diving-accident survivor named Ian Burkhart and got Burkhart’s own hand to open and close for the first time in four years. The result was the 2016 Nature paper (Bouton, Shaikhouni, Annetta, Bockbrader, Friedenberg, Nielson, Sharma et al.) that showed cortical control of functional movement in a human with quadriplegia. Two years later, roughly, Bouton moved from Battelle to the Feinstein Institutes for Medical Research at Northwell Health on Long Island, took the Vice President of Advanced Engineering role there, built the Center for Bioelectronic Medicine, and started work on a second-generation system called the double neural bypass. On 16 July 2026 the double neural bypass results were published on the cover of Nature Medicine, single-participant, tested in a Massapequa, New York man named Keith Thomas who had broken his neck in a pool dive on 18 July 2020 and was now feeding himself again. Inside BCI covered that paper on 18 July. On Monday 27 July 2026 the same Chad Bouton announced, through a Stamford, Connecticut company called Neuvotion, that the first commercial product from the platform will launch this fall. That product is NeuStim NN-01. It is a wearable peripheral neuromuscular stimulator. It is not, strictly, a brain-computer interface. Chad Bouton is Neuvotion’s founder and chief executive, and he holds an exclusive worldwide license from Feinstein for the underlying neurostimulation intellectual property that runs from the 2016 Battelle work through the 2026 Nature Medicine paper into the 2026 commercial launch.

What the announcement actually says and what it does not

Neuvotion’s 27 July Business Wire release is packaged in a way that requires careful unpacking. The headline is “Neuvotion Announces Commercialization of Brain-Computer Interface and Brain-Body Interface Technologies; Related Clinical Study Published in Nature Medicine.” Read from top to bottom, the release ties three separate items together: the fall 2026 commercial launch of NeuStim, the 16 July 2026 Nature Medicine paper, and the platform-level architecture Bouton has been building for a decade. The way the release stacks them creates the impression that a full brain-computer interface plus brain-body interface is now available for order. That is not the operational reality.

The only Neuvotion product with an FDA clearance in hand is NeuStim NN-01, cleared under 510(k) K240632 on 22 November 2024 (not a new clearance) with the Bioness NESS H200 Wireless Hand Rehabilitation System (K123636) as the predicate device. The product code is GZI, the regulation is 21 CFR 882.5810, and the device class is II. The FDA-cleared indication is improvement of hand function and active range of motion in patients with hemiplegia due to stroke or upper-limb paralysis due to C5 spinal cord injury, with an additional label for neuromuscular electrical stimulation applications including hand range of motion, prevention of disuse atrophy, blood-circulation support, spasm relaxation, and muscle re-education. The device is right-hand only per the FDA label. It is professional healthcare facility use only rather than home use (its predicate H200 does have a home-use variant; NeuStim’s clearance is a narrower subset). It is prescription-only. The clearance was based on bench testing; no clinical trial data was submitted. The launch this fall is a real commercial event; the product is real; but it enters the Bioness H200 and Onward Medical ARC-EX segment of the FDA-cleared upper-limb rehabilitation market, not the Neuracle NEO, Precision Neuroscience Layer 7, Synchron Stentrode, Neuralink N1, ABILITY Neurotech, or StairMed WRS02 invasive brain-computer interface market.

The intracortical brain-computer interface half of Bouton’s double neural bypass system, the part that reads motor intent from primary motor cortex through implanted Blackrock microelectrode arrays and closes a sensory loop through patterned intracortical microstimulation, is not commercially available. It is investigational under FDA IDE G170200 (Northwell Health IRB no. 17-0840; ClinicalTrials.gov NCT03680872), tested to date in a single participant (Keith Thomas), and reported for the first time in the July Nature Medicine paper. Neuvotion’s release does not obscure that the full system is investigational, but the headline framing folds it into the same commercialisation announcement as NeuStim. The precise reading is that Neuvotion is commercialising the peripheral neuromuscular stimulation half of the double neural bypass platform first, with the intracortical BCI half remaining in early-feasibility clinical study for the time being. A separate Neuvotion product called FocalStim, described in the April 2026 release as “precise spinal cord stimulation for improving and accelerating movement recovery outcomes,” is also still in development with an expected 2027 introduction.

Who Neuvotion is

The company is Neuvotion, Inc., headquartered at 165 Club Road, Stamford, Connecticut. Chad Bouton is founder, president, and chief executive. Dave Jones is chief operating officer and regulatory lead, bringing forty-five years of medical device experience per the company’s own materials. Rory Murphy, MD (neurosurgeon at Barrow Neurological Institute), Sandeep Singh, MD (chief medical officer at Good Shepherd Rehabilitation Network), and Dan Sciubba, MD (chair of neurosurgery at Northwell Health, formerly Johns Hopkins), sit as scientific and clinical advisors. Michael Spigel, president and chief executive of Good Shepherd Rehabilitation Network, is on the strategy side. Named clinical collaborators include Northwell Health, Good Shepherd Rehabilitation Network, and Barrow Neurological Institute. Contract engineering is handled through Intelligent Product Solutions in a partnership announced 17 December 2024 and expanded for NeuStim commercialisation. The company describes itself as an early-stage medical device company. The only publicly disclosed funding round is an additional $1.25 million raise in April 2023 to support NeuStim commercialisation; the “additional” language implies prior undisclosed rounds, and the cumulative funding history, investor list, and post-money valuation have not been publicly stated in verifiable sources.

Bouton’s dual role structure at Feinstein and Neuvotion is worth stating explicitly. The Nature Medicine paper’s affiliation for Bouton is the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell in Manhasset, and his corresponding-author email is cbouton@northwell.edu. As of the paper’s publication date on 16 July 2026 and the ClinicalTrials.gov trial record last-updated date of 9 March 2026, he retains both the Vice President of Advanced Engineering title and the Managing Director role at Feinstein’s Center for Bioelectronic Medicine. His concurrent Neuvotion role is founder, president, and chief executive. The paper’s competing-interests statement discloses this dual position verbatim: “C.E.B. has financial interests in Neuvotion, Inc., a medical device company developing neurotechnologies for restoring function after stroke or spinal cord injury, and Sanguistat, LLC, a company developing neurostimulation technologies to reduce blood loss; he also has multiple patents in the field of neuroprosthetics and related fields. The other authors declare no competing interests.” Neuvotion’s Feinstein license is the corporate translation vehicle for research generated in Bouton’s own Feinstein laboratory. Sanguistat, LLC is Bouton’s second commercial venture, focused on neurostimulation to reduce surgical blood loss.

What Bouton said, and how narrow the “first” claim actually is

Two Bouton quotes carry the strategic weight of the 27 July release. The first: “This study is the culmination of many years of work. This is the first BCI to support recovery of both movement and sensation, while promoting long term gains. We are not just bypassing the injury, we are ‘rewiring’ the nervous system to promote neuroplasticity and help users worldwide regain sensation, get stronger, and regain independence - even after the system is turned off.” The second: “This study marks a defining milestone. For decades, we’ve been pushing the boundaries of what’s possible. Our goal is to translate this breakthrough from research to real-world clinical care, helping people regain movement, sensation, and ultimately, independence.”

The first-BCI-to-support-both-movement-and-sensation claim requires precise reading before it survives a Tier 1 fact-check. Movement restoration through cortical BCI in a person with paralysis was demonstrated by BrainGate’s Matthew Nagle in 2004 (Hochberg, Serruya, Friehs, Mukand, Saleh, Caplan, Branner, Chen, Penn, Donoghue; Nature 442:164-171, 2006), by the Bouton-Battelle-Burkhart Ohio State study in 2014 (Bouton et al., Nature 533:247-250, 2016), and by multiple subsequent programmes including Pitt-UChicago, Stanford, Neuralink, Paradromics, Synchron, Neuracle, StairMed, and Precision Neuroscience. Sensory restoration through intracortical microstimulation of somatosensory cortex was demonstrated by Sharlene Flesher and colleagues at Pittsburgh in 2016, and reported in the ten-year safety and efficacy update from Charles Greenspon and Robert Gaunt in Science Translational Medicine on 15 July 2026, one day before the double neural bypass Nature Medicine paper. Inside BCI covered that ten-year Pitt paper on 18 July. What is genuinely new in the double neural bypass work is the combination of intracortical motor decoding plus cortical microstimulation plus transcutaneous spinal cord stimulation, with functional gains that persist for months after the stimulation is turned off. The persistence-after-stimulation-ends finding is the narrower, defensible superlative. Written flat, “first BCI to support recovery of both movement and sensation” collapses; scoped precisely to the durable neuroplasticity claim in a single participant, it holds.

The April 2026 Neuvotion release also positioned NeuStim as part of an “AI-guided Brain-Body Interface Platform.” The AI-guided framing does not appear in the FDA 510(k) clearance letter, which describes user-directed manual electrode mapping through a touch-screen interface. Any InsideBCI reader who reads the FDA clearance letter alongside the marketing copy will spot the distinction. It is worth pointing out that the FDA clearance is what defines what NeuStim can legally claim in medical labelling; the AI-guided characterisation applies at the platform-narrative level rather than the FDA-approved-indication level.

Where this sits in the broader arc

The most useful frame for the 27 July announcement is that it is the commercial follow-through on the Nature Medicine science story Inside BCI covered nine days ago. The Bouton career arc from Battelle NeuroLife through Feinstein double neural bypass into Neuvotion’s commercial rollout is a decade-long single trajectory. The peripheral neuromuscular stimulation half of that trajectory has now cleared the FDA and is entering the crowded upper-limb rehabilitation market alongside the Bioness NESS H200 (K123636), Onward Medical’s FDA De Novo-cleared ARC-EX transcutaneous spinal cord stimulator for cervical SCI upper-limb function, MyndMove, Restorative Therapies FES devices, and other rehabilitation-focused peripheral electrical stimulation products. That is not a brain-computer interface market. It is a rehabilitation-device market where NeuStim’s competitive positioning depends on clinical uptake at rehabilitation networks such as Good Shepherd, on payer coverage decisions, and on whether the underlying platform story helps Neuvotion win against incumbents whose devices have longer clinical and reimbursement track records.

The intracortical brain-computer interface half of the double neural bypass is a different commercial arc entirely. It sits in the same investigational-device territory as Neuralink’s N1, Paradromics’ Connexus, Precision Neuroscience’s Layer 7 (specifically the surface-array chronic version, currently pre-EFS), Synchron’s Stentrode, ABILITY Neurotech’s optical-link ECoG platform, StairMed’s WRS02, and Neuracle NEO before its Chinese commercial approval. What Bouton and Neuvotion are proposing, at least strategically, is that the peripheral neuromuscular stimulation product line generates revenue and clinical credibility while the intracortical BCI matures through additional participants beyond Keith Thomas. Whether that dual-track commercialisation plays out or whether Neuvotion remains fundamentally a peripheral stimulation company with a Feinstein research licence attached is the question the next three years will answer.

What to watch

Watch NeuStim’s actual commercial rollout this fall. FDA clearance is not the same as clinical uptake. Whether NeuStim is prescribed inside Good Shepherd Rehabilitation Network and other partner facilities at meaningful volume in the six months after launch is the operational milestone that separates a real commercial product from a press-release product. The Bioness H200 has decades of prescriber familiarity and payer coverage; NeuStim enters the market cold.

Watch whether Neuvotion enrols a second participant on the double neural bypass IDE G170200 trial. The Nature Medicine paper is single-participant. The 2028 Feinstein-side timeline for scaling the platform depends on additional participants beyond Keith Thomas. If a second participant lands in the second half of 2026 or the first half of 2027, the commercial and clinical arcs both accelerate. If Keith Thomas remains the sole participant through the end of 2026, the timeline slips.

Watch how Neuvotion positions against Onward Medical specifically. Onward’s ARC-EX, cleared under FDA De Novo in 2024 for upper-limb function restoration in cervical SCI, is the closest direct competitor to NeuStim in the FDA-cleared non-invasive commercial space. Onward has clinical trial infrastructure, reimbursement coverage development, and a public-market listing on Nasdaq. Neuvotion is early-stage and privately held. Whether NeuStim differentiates on device architecture, on price, on clinician workflow, or on the integrated platform story is the commercial question.

Watch the FocalStim launch timeline slip. Bouton’s April 2026 language committed to a 2027 FocalStim introduction. Whether the spinal cord stimulation product line launches on that schedule or gets absorbed into the broader Neuvotion narrative without a firm product date is the near-term signal on whether Neuvotion’s second product line is on track.

Sources

news Neuvotion NeuStim Chad-Bouton Feinstein-Institutes Northwell-Health Keith-Thomas double-neural-bypass FDA-510k Bioness-H200 Onward-ARC-EX hand-rehabilitation stroke cervical-spinal-cord-injury Sanguistat Battelle-NeuroLife Ian-Burkhart State-Patchwork-posture

What the announcement actually says and what it does not

Who Neuvotion is

What Bouton said, and how narrow the “first” claim actually is

Where this sits in the broader arc

What to watch

Weekly BCI Brief in your inbox